Characteristics of patients with alcohol dependence seeking baclofen treatment in France: A two-centre comparative cohort study

Alcohol and Alcoholism

Volumn 51, Issue 6, 2016, Pages 664-669

  Simioni, Nicolas ^a,b   Preda, Cristian ^c   Deken, Valérie ^c   Bence, Camille ^a   Cottencin, Olivier ^a,d   Rolland, Benjamin ^a,e  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b EPSM Val de Lys Artois   (France)

^c UNIV LILLE   (France)

^d UNIV LILLE   (France)

^e CHU Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FRANCE; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTIVATION; OUTPATIENT; PATIENT REFERRAL; PATIENT SELF REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; MULTICENTER STUDY; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA;

ALCOHOLISM; BACLOFEN; FEMALE; FRANCE; GABA-B RECEPTOR AGONISTS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 84994494464     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agw011     Document Type: Article

References (20)

1. Adamson SJ, Heather N, Morton V, et al. (2010) Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes. Alcohol Alcohol 45:136-42.
2. Agence Française du Médicament et des produits de santé (ANSM). (2013) Réunion du Comité technique de Pharmacovigilance-CT012013023-Séance du 16 avril 2013. http://ansm.sante.fr/var/ansm_site/storage/original/application/ce293ec4ef97ea3ee0c5fd1dfcf4dfe7.pdf (14 December 2015, date last accessed).
3. Agence Française du Médicament et des produits de santé (ANSM). (2014) [Recommandation temporaire d'utilisation (RTU) pour le baclofène-Point d'information] Temporary recommendation for use (TRU) for baclofen. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Une-recommandation-temporaire-d-utilisation-RTU-est-accordee-pour-lebaclofene-Point-d-information (10 November 2015, date last accessed).
4. Ameisen O. (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 40:147-50.
5. Ameisen O. (2008) Le dernier verre. Paris: Editions Denoël. Andréasson S, Danielsson AK, Wallhed-Finn S. (2013) Preferences regarding treatment for alcohol problems. Alcohol Alcohol 48:694-9.
6. Dupouy J, Fournier J-P, Jouanjus E, et al. (2014) Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns-a cohort study. Eur Neuropsychopharmacol 24:192-9.
7. Luquiens A, Aubin HJ. (2014) Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene. Patient Prefer Adherence 8:1347-52.
8. Morley KC, Baillie A, Leung S, et al. (2014) Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol 49:654-60.
9. Oleski J, Mota N, Cox BJ, et al. (2010) Perceived need for care, help seeking, and perceived barriers to care for alcohol use disorders in a national sample. Psychiatr Serv 61:1223-31.
10. Rehm J, Shield K, Rehm M, et al. (2012) Alcohol Consumption, Alcohol Dependence, and Attributable Burden of Disease: Potential Gains from Effective Interventions for Alcohol Dependence. Toronto, ON: Centre for Addiction and Mental Health.
11. Rehm J,Manthey J, Struzzo P, et al. (2015)Who receives treatment for alcohol use disorders in the European Union? A cross-sectional representative study in primary and specialized health care. Eur Psychiatry 30:885-93.
12. Rolland B, Deheul S, Danel T, et al. (2010) A system of prescriptions without drug approval: example of baclofen. [Article in French]. Therapie 65:511-8.
13. Rolland B, Bordet R, Cottencin O. (2012) Alcohol-dependence: the current French craze for baclofen. Addiction 107:848-9.
14. Rolland B, Paille F, Fleury B, et al. (2014) Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey. PLoS One 9:e98062.
15. Rolland B, Labreuche J, Duhamel A, et al. (2015) Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. doi: 10.1016/j.euroneuro. 2015.05.008.
16. Rolland B, Paille F, Gillet C, et al. (2016). Pharmacotherapy for alcoholdependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther 22:25-37.
17. Sachais BA, Logue JN, Carey MS. (1977) Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 34:422-8.
18. Saunders SM, Zygowicz KM, D'Angelo BR. (2006) Person-related and treatment-related barriers to alcohol treatment. J Subst Abuse Treat 30:261-70.
19. Sobell L, Sobell MB. (1992). Timeline follow-back: a technique for assessing self-reported ethanol consumption. In Allen J, Litten RZ (eds), Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press, 41-72.
20. World Health Organization. (2007) International Classification of Diseases and Related Health Problems, 10th Revision. Geneva: World Health Organization.